Valneva SE
Tracked across 4 events · 49 articles · First seen Apr 02, 2026 · Last active Aug 17, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Impact: Valneva SE is the company issuing declarations regarding its shares and voting rights, providing transparency to the market.
Apr 03, 2026 · 7 articles
Regulatory
The European Union — European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for PF-07307405, a 6-valent OspA-based Lyme disease vaccine candidate co-developed by Pfizer and Valneva SE. The validation allows the EMA…
Impact: Valneva is the co-developer and stands to benefit from milestone payments and royalties. The validation is a major milestone for the company, potentially increasing its valuation.
Aug 14, 2026 · 12 articles
Tech
Impact: Valneva SE is a pharmaceutical company collaborating with Pfizer on the development of a Lyme disease vaccine. Their joint effort to seek regulatory approval could lead to a significant new product for the company.
Apr 30, 2026 · 24 articles
90
European Union — European Medicines Agency accepted application Valneva SEEMA validates...
80
Valneva SE declared shares, voting rightsValneva declares shares,...
80
Valneva SE announced validationEMA validates...
ERGEN INTELLIGENCE
Track Valneva SE live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard